Roche’s Faricimab Shows Sustained Vision Benefits in Phase III Study for Retinal Vein Occlusion
Swiss pharmaceutical giant Roche (SWX: ROG) has released interim Phase III data for its bispecific...
CDE Reports 35.84% Increase in Drug Filings for 2023 with Focus on Innovation and Rare Diseases
The Center for Drug Evaluation (CDE) has released its annual drug review report for 2023,...
J&J’s Gene Therapy for X-linked Retinitis Pigmentosa Receives CDE Nod for Breakthrough Designation
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...
German Tech Giant Merck Launches Digital Hub in Singapore to Boost Healthcare and Semiconductor Research
Merck KGaA (ETR: MRK), a leading German technology company, last week inaugurated a digital hub...
Johnson & Johnson’s Talquetamab and Daiichi Sankyo’s Enhertu Eye Priority Review in China
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...
Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies
Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its...
Beckton Dickinson’s Q1 Results Affected by Volume-Based Procurement, Life Sciences Growth
US-based medical technology company Beckton Dickinson (BD; NYSE: BDX) has reported its financial results for...
SciClone and Menarini File for Import License of Antibacterial Drug Vaborem in Macau
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that its Italy-based strategic partner Menarini has submitted...
Baidu Health Partners with Souyao to Boost Offline Pharmacy Services in China
Baidu Health has entered into a partnership with Beijing-based pharmaceutical business service provider Souyao. The...
AbbVie Reports $54.3 Billion in 2023 Revenues Amid Humira Erosion and Segment Variability
AbbVie (NYSE: ABBV) reported revenues of $54.3 billion for 2023, reflecting a 5.9% year-on-year decline...
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...
Biotech Pharmaceutical Secures Approval for Nimotuzumab in Head and Neck Cancer Treatment
Sino-Cuban joint venture Biotech Pharmaceutical Limited (BPL) has secured another indication approval in China for...
BMS Sees Mixed Results in 2023: Growth in New Products Offset by Loss of Exclusivity
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 2% year-on-year contraction in 2023 revenues, excluding...
China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates
China’s National Cancer Center (NCC) has released the latest national cancer statistics, approved by the...
Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China
Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent...
Chongqing Genrix Biopharmaceutical Gets NMPA Clearance for IL-4Rα mAb Candidate GR1802
Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has announced that it...
Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has...
Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug...
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in...
China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with...